Plakophilin-2 accelerates cell proliferation and migration through activating EGFR signaling in lung adenocarcinoma

Background Plakophilin 2 (PKP2), encodes a plakophilin protein that belongs to the member of desmosomal proteins. It has been reported that high expression of PKP2 is associated with several types of cancer in humans. However, the role of PKP2 in lung cancer remains obscure. Methods: PKP2 expression was investigated in non-small cell lung cancer (NSCLC) tissues and non-tumor tissues by performing immunohistochemistry on a tissue microarray and using The Cancer Genome Atlas (TCGA) database. Kaplan-Meier survival analysis and multivariate Cox-regression analysis were performed to identify the clinical significance of PKP2. 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2Htetrazolium (MTS), colony formation, Transwell and xenograft tumor growth/metastasis assays were conducted to evaluate the biological function of PKP2 in vitro and in vivo. Gene set enrichment analysis (GSEA), WB and immunoprecipitation (IP) assay were utilized to explore the potential downstream signaling pathway and molecule mechanism of PKP2 in lung adenocarcinoma (LUAD). Results: Analysis of PKP2 expression and clinicopathological parameters reveals a significant correlation of PKP2 expression with gender (n = 1020, P < 0.001) and histological type (n = 1020, P < 0.001). Subsequently, our results demonstrated that high PKP2 expression is not associated with poor survival in different gender of lung cancer patients, and is an unfavorable and independent prognostic biomarker for LUAD patients, but not for LUSC patients. Gene set enrichment analysis (GSEA) revealed that PKP2 expression is positively associated with EGFR signaling in LUAD. Further, in vitro and in vivo assays revealed that PKP2 promotes cell proliferation, migration and invasion through activating EGFR signaling pathway in LUAD cells. Conclusion: Our study provides the basis for further investigation of the function and molecular mechanism by which upregulation of PKP2 promotes the development and progression of LUAD. PKP2 may serve as a potential target for anticancer therapies.